The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560
A Clinical Handbook of Psychological Disorders: A Step-by-Step Treatment Manual, Fifth Edition
HINDMAN, R., & BECK, J. S. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000087 · Cited by 472
Rauch, S. L., Savage, C. R., Alpert, N. M., Fischman, A. J., & Jenike, M. A. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00145-5 · Cited by 393
Ledgerwood, L., Richardson, R., & Cranney, J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.023 · Cited by 243
Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90687-4 · Cited by 190
Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications
Richardson, R., Ledgerwood, L., & Cranney, J. (2004) · Learning & Memory · doi:10.1101/lm.78204 · Cited by 185
A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear
Guastella, A. J., Dadds, M. R., Lovibond, P. F., Mitchell, P., & Richardson, R. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.006 · Cited by 164
Cited by
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective
Grupe, D. W., & Nitschke, J. B. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3524 · Cited by 2,007
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adding d-cycloserine may hasten the onset of improvements with ERP, with significant benefits over placebo during the first four or five ERP sessions [698-700], but this effect has not been seen in all studies [701].”
BackgroundTargeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic
Ressler, K. J., & Mayberg, H. S. (2007) · Nature Neuroscience · doi:10.1038/nn1944 · Cited by 1,007
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways
Milad, M. R., & Rauch, S. L. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.003 · Cited by 847
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Extinction circuits for fear and addiction overlap in prefrontal cortex
Peters, J., Kalivas, P. W., & Quirk, G. J. (2009) · Learning & Memory · doi:10.1101/lm.1041309 · Cited by 736
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“A series of small randomised placebo-controlled studies suggest that administration of d-cycloserine may hasten the response to CBT, but provide no evidence that the overall effectiveness of CBT is enhanced [I (PCT)] (Kushner et al., 2007; Storch et al., 2010; Wilhelm et al., 2008).”
BackgroundÖst, L.-G., Havnen, A., Hansen, B., & Kvale, G. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.06.003 · Cited by 655
Mahan, A. L., & Ressler, K. J. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.06.007 · Cited by 613
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Implications of memory modulation for post-traumatic stress and fear disorders
Parsons, R. G., & Ressler, K. J. (2013) · Nature Neuroscience · doi:10.1038/nn.3296 · Cited by 476
How the Neurocircuitry and Genetics of Fear Inhibition May Inform Our Understanding of PTSD
Jovanovic, T., & Ressler, K. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09071074 · Cited by 437
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“, 2013c) and OCD [(Chasson et al., 2010; Farrell et al., 2013; Kushner et al., 2007; Storch et al., 2010; Wilhelm et al., 2008) but see (Mataix-Cols et al.”
BackgroundMethodRothbaum, B. O., Price, M., Jovanovic, T., Norrholm, S. D., Gerardi, M., Dunlop, B., Davis, M., Bradley, B., Duncan, E. J., Rizzo, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13121625 · Cited by 388
Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder
Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050776 · Cited by 358
The Science of Cognitive Therapy
Hofmann, S. G., Asmundson, G. J. G., & Beck, A. T. (2013) · Behavior Therapy · doi:10.1016/j.beth.2009.01.007 · Cited by 366
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.011 · Cited by 326
Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., Frumento, P., de Kleine, R. A., Difede, J., Dunlop, B. W., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3955 · Cited by 288
Self-citationFear extinction and BDNF: translating animal models of PTSD to the clinic
Andero, R., & Ressler, K. J. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00801.x · Cited by 276
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
“Two groups have reported successful use of DCS in augmentation with exposure therapy for adult patients (Kushner et al., 2007; Wilhelm et al., 2008).”
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G., Eisenmenger, K., Krystal, J. H., & Pollack, M. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.036 · Cited by 251
de Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.033 · Cited by 220
Brimberg, L., Benhar, I., Mascaro-Blanco, A., Alvarez, K., Lotan, D., Winter, C., Klein, J., Moses, A. E., Somnier, F. E., Leckman, J. F., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.56 · Cited by 202
McLean, C. P., & Foa, E. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.94 · Cited by 199
Self-citationLitz, B. T., Salters-Pedneault, K., Steenkamp, M. M., Hermos, J. A., Bryant, R. A., Otto, M. W., & Hofmann, S. G. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.05.006 · Cited by 196
Challenges in Developing Novel Treatments for Childhood Disorders: Lessons from Research on Anxiety
Pine, D. S., Helfinstein, S. M., Bar-Haim, Y., Nelson, E., & Fox, N. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.113 · Cited by 194
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Hofmann, S. G., Ellard, K. K., & Siegle, G. J. (2012) · Cognition and Emotion · doi:10.1080/02699931.2011.579414 · Cited by 132
Exposure therapy in eating disorders revisited
Koskina, A., Campbell, I. C., & Schmidt, U. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.11.010 · Cited by 127
Hofmann, S. G., Smits, J. A. J., Rosenfield, D., Simon, N., Otto, M. W., Meuret, A. E., Marques, L., Fang, A., Tart, C., & Pollack, M. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070974 · Cited by 121
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“Three small studies (Kushner et al., 2007; Storch et al., 2008; Wilhelm et al., 2008) each used different doses (100 mg, 125 mg and 250 mg) and different timings (1 h, 2 h and 4 h before ERP).”
BackgroundD-cycloserine facilitates context-specific fear extinction learning
Bouton, M. E., Vurbic, D., & Woods, A. M. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.07.003 · Cited by 118
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler et al., 2004; social phobia: Guastella et al., 2008; Hofmann et al., 2006; obsessive–compulsive disorder: Kushner et al., 2007).”
BackgroundSmits, J. A. J., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., & Hofmann, S. G. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.020 · Cited by 114
“, 2004), and several showing either relatively weak effects (Kushner et al., 2007; Wilhelm et al., 2008), no effects (Guastella et al.”
BackgroundDoes D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
Translating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders
Ressler, K. J. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20010055 · Cited by 104
Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine
Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T., Welsh, K. S., & Wilhelm, S. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.03.007 · Cited by 106
Empirically Supported Treatments for Panic Disorder
McHugh, R. K., Smits, J. A. J., & Otto, M. W. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.005 · Cited by 106
Briscione, M. A., Jovanovic, T., & Norrholm, S. D. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00088 · Cited by 105
New Directions in the Cognitive-Behavioral Treatment of OCD: Theory, Research, and Practice
Abramowitz, J. S., Blakey, S. M., Reuman, L., & Buchholz, J. L. (2018) · Behavior Therapy · doi:10.1016/j.beth.2017.09.002 · Cited by 98
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2010.01198.x · Cited by 87
“, 2006), and obsessive compulsive disorder (Kushner et al., 2007; Wilhelm et al., 2008).”
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80
Grillon, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.017 · Cited by 80
“While traditional anxiolytics such as the benzodiazepines or selective serotonin reuptake inhibitors reduce symptom expression, DCS facilitates the effectiveness of EBT (1-5).”
Novel treatment approaches for refractory anxiety disorders
Pollack, M. H., Otto, M. W., Roy-Byrne, P. P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · Depression and Anxiety · doi:10.1002/da.20329 · Cited by 77
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
Reinecke, A., Thilo, K., Filippini, N., Croft, A., & Harmer, C. J. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.07.017 · Cited by 75
Augmentation of exposure therapy with post-session administration of D-cycloserine
Tart, C. D., Handelsman, P. R., DeBoer, L. B., Rosenfield, D., Pollack, M. H., Hofmann, S. G., Powers, M. B., Otto, M. W., & Smits, J. A. J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.024 · Cited by 75
Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans
Klumpers, F., Denys, D., Kenemans, J. L., Grillon, C., van der Aart, J., & Baas, J. M. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431624 · Cited by 72
Woods, A. M., & Bouton, M. E. (2008) · Learning & Memory · doi:10.1101/lm.1078508 · Cited by 70
Enhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.007 · Cited by 70
Bontempo, A., Panza, K. E., & Bloch, M. H. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07356 · Cited by 69
Langton, J. M., & Richardson, R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.32 · Cited by 63
“…Ledgerwood et al, 2003), has also been shown to facilitate exposure-based therapy in humans diagnosed with a range of anxiety disorders including acrophobia (Ressler et al, 2004), social phobia (Hofmann et al, 2006; Guastella et al, 2008), and obsessive–compulsive disorder (Kushner et al, 2007).”
BackgroundGlutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
d-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders
Hofmann, S. G., Wu, J. Q., & Boettcher, H. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-11 · Cited by 59
McGuire, J. F., Lewin, A. B., & Storch, E. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.934677 · Cited by 57
“In four RCTs, participants receiving DCS and exposure-based treatment exhibited small-to-moderate enhanced treatment effects at post-treatment and follow-up assessments on the Children’s/ Yale-Brown Obsessive-Compulsive Scale that did not reach statistical significance [43,45,46,48].”
BackgroundResultKuriyama, K., Honma, M., Soshi, T., Fujii, T., & Kim, Y. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2353-x · Cited by 54
D-cycloserine and cocaine cue reactivity: preliminary findings
Price, K. L., McRae-Clark, A. L., Saladin, M. E., Maria, M. M. M.-S., DeSantis, S. M., Back, S. E., & Brady, K. T. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990903384332 · Cited by 54
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
Bürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173660 · Cited by 41
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000330 · Cited by 39
Kuriyama, K., Honma, M., Yoshiike, T., & Kim, Y. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.045 · Cited by 36
Leveraging cognitive neuroscience for making and breaking real-world habits
Buabang, E. K., Donegan, K. R., Rafei, P., & Gillan, C. M. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2024.10.006 · Cited by 34
CBT for pharmacotherapy non-remitters—a systematic review of a next-step strategy
Rodrigues, H., Figueira, I., Gonçalves, R., Mendlowicz, M., Macedo, T., & Ventura, P. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.025 · Cited by 35
Mao, L., Hu, M., Luo, L., Wu, Y., Lu, Z., & Zou, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.973838 · Cited by 29
Sayyah, M., Olapour, A., Saeedabad, Y. S., Yazdan Parast, R., & Malayeri, A. (2012) · Nutrition · doi:10.1016/j.nut.2011.11.027 · Cited by 28
Tolin, D. F. (2017) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.08.007 · Cited by 25
Innovations in the delivery of exposure and response prevention for obsessive-compulsive disorder
Patel, S. R., Comer, J., & Simpson, H. B. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_202 · Cited by 24
Farrell, L. J., Waters, A. M., Tiralongo, E., Mathieu, S., McKenzie, M., Garbharran, V., Ware, R. S., Zimmer‐Gembeck, M. J., McConnell, H., Lavell, C., et al. (2022) · Depression and Anxiety · doi:10.1002/da.23242 · Cited by 23
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Gragnani, A., Zaccari, V., Femia, G., Pellegrini, V., Tenore, K., Fadda, S., Luppino, O., Basile, B., Cosentino, T., Perdighe, C., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102762 · Cited by 8
Wheaton, M. G., Schwartz, M. R., Pascucci, O., & Simpson, H. B. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-05 · Cited by 7
A precision medicine approach to pharmacological adjuncts to extinction: A call to broaden research
King, G., Baker, K. D., Bisby, M. A., Chan, D., Cowan, C. S. M., Stylianakis, A. A., Zimmermann, K. S., & Richardson, R. (2019) · Psychopharmacology · doi:10.1007/s00213-018-4999-0 · Cited by 6
Novel approaches in treatment of pediatric anxiety
Park, J. M., & Geller, D. A. (2014) · F1000Prime Reports · doi:10.12703/p6-30 · Cited by 2
“Among the eight human studies using DCS as an adjunct to psychotherapy, there have been few to no adverse events [57,59,61,62].”
Background
Metadata
- Authors
- Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., McCabe, J., Peterson, J., & Foa, E. B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 62
- Issue
- 8
- Pages
- 835-838
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2091982759
- Cited by
- 384
- References
- 13
- FWCI
- 37.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.